nimotuzumab

Overview

Nimotuzumab is a humanized anti-EGFR monoclonal antibody targeting EGFR. It is evaluated in nasopharyngeal carcinoma (NPC), where EGFR is overexpressed in a substantial fraction of tumors and drives proliferation, metastasis, and resistance via PI3K/AKT and MAPK pathways.

Evidence in the corpus

• Nimotuzumab anti-EGFR monoclonal antibody evaluated in NPC where EGFR is overexpressed; listed alongside cetuximab and pimurutamab as EGFR-targeting antibodies, and alongside EGFR ADCs (becotatug vedotin) and bispecific ADCs, as part of the EGFR-targeting therapeutic landscape in R/M NPC PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.